Abstract
The aim was to evaluate the association of CETP (rs5882 and rs708272) single nucleotide polymorphisms with the presence, invasiveness, hormonal activity and recurrence of pituitary adenoma (PA). The study group included 142 patients with PA and the control group, 753 healthy subjects. The genotyping of CETP (rs5882 and rs708272) was performed using a real-time PCR method. After statistical analysis we found that CETP rs708272 genotype G/A under the over-dominant model was associated with the decreased odds of PA (OR=0.637; 95%CI: 0.443-0.917; P=0.015), active PA (OR=0.538; 95%CI: 0.335-0.865; P =0.01) and non-recurrent PA (OR=0.602; 95% CI: 0.402 - 0.902; P =0.014). When compared to controls, the rs708272 genotype G/A was less frequent in the active PA subgroup (37.5% vs 52.7%, P =0.009) and the non-recurrent PA subgroup (40.2% vs 52.7%, P=0.013), while the rs5882 genotype A/A was less frequent in the non-recurrent PA subgroup (37.5% vs 46.2%, P=0.015). Our study showed that CETP rs708272 genotype G/A may be associated with a decreased risk of PA.
Highlights
Pituitary adenomas (PAs) are a group of diverse neoplasms which typically arise from adenohypophysis and rarely metastasize[1]
When we compared frequencies of genotypes and alleles in the PA and control groups, we found that the rs5882 G/A genotype was less frequent in the PA group than the control group (38% vs 46.2%, P=0.033) while the rs708272 G/G genotype was more frequent in the PA group than the control group (38.7% vs 29.8%, P=0.034)
When we analyzed the rs708272 polymorphism, we found that co-dominant (G/A OR=0.605; 95%CI: 0.405–0.905; and A/A OR=0.864; 95% CI: 0.5221.429; P=0.043), dominant (OR=0.670; 95%CI: 0.462– 0.972; P=0.035) and over-dominant (OR=0.637; 95%CI: 0.443–0.917; P=0.015) variables were statistically significant but only the latter result remained significant after the Bonferroni correction (Table 2)
Summary
Pituitary adenomas (PAs) are a group of diverse neoplasms which typically arise from adenohypophysis and rarely metastasize[1]. PAs can be invasive and noninvasive, recurrent and non-recurrent[4]. Even if PA usually is non-malignant, it tends to recur locally after excision[4,5]. Another problem is the aggressiveness of PA – it does not have a capsule and can grow invasively into surrounding tissues[6]. Not all of these tumors are symptomatic and it is quite hard to diagnose PA while it is in early stages[4,7]. Scientists are trying to find biomarkers which could help detect PA at early stages[1,7]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
